Report cover image

Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 196 Pages
SKU # APRC20557237

Description

Summary

According to APO Research, the global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market include Alkeus Pharmaceuticals, Biovista, Editas Medicine, GenSight Biologics, Ixchel Pharma, Khondrion, Mitotech, ProQR Therapeutics and Spark Therapeutics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy), also provides the sales of main regions and countries. Of the upcoming market potential for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) sales, projected growth trends, production technology, application and end-user industry.

Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Segment by Company

Alkeus Pharmaceuticals
Biovista
Editas Medicine
GenSight Biologics
Ixchel Pharma
Khondrion
Mitotech
ProQR Therapeutics
Spark Therapeutics
Stealth BioTherapeutics
Usher Syndrome
Amgen
Sanofi
Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Segment by Type

Dominant Optic Atrophy
Recessive Optic Atrophy
Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Segment by Application

Hospitals
Medical Research Institute
Eye Clinics
Other
Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) significant trends, drivers, influence factors in global and regions.
6. To analyze Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) industry.
Chapter 3: Detailed analysis of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

196 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2020-2031)
1.2.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume (2020-2031)
1.2.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Dynamics
2.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Trends
2.2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Drivers
2.3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Opportunities and Challenges
2.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Restraints
3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market by Company
3.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Company Revenue Ranking in 2024
3.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Company (2020-2025)
3.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Company (2020-2025)
3.4 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Average Price by Company (2020-2025)
3.5 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Company Ranking (2023-2025)
3.6 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Company Manufacturing Base and Headquarters
3.7 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Company Product Type and Application
3.8 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market by Type
4.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Type Introduction
4.1.1 Dominant Optic Atrophy
4.1.2 Recessive Optic Atrophy
4.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Type
4.2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Type (2020-2031)
4.2.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume Share by Type (2020-2031)
4.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Type
4.3.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Type (2020-2031)
4.3.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type (2020-2031)
5 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market by Application
5.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Application Introduction
5.1.1 Hospitals
5.1.2 Medical Research Institute
5.1.3 Eye Clinics
5.1.4 Other
5.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Application
5.2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Application (2020-2031)
5.2.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume Share by Application (2020-2031)
5.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Application
5.3.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Application (2020-2031)
5.3.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application (2020-2031)
6 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Regional Sales and Value Analysis
6.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region (2020-2031)
6.2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region: 2020-2025
6.2.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region (2026-2031)
6.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Region (2020-2031)
6.4.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Region: 2020-2025
6.4.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Region (2026-2031)
6.5 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2020-2031)
6.6.2 North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2020-2031)
6.7.2 Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2020-2031)
6.8.2 Asia-Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2020-2031)
6.9.2 South America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2020-2031)
6.10.2 Middle East & Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Country, 2024 VS 2031
7 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Country-level Sales and Value Analysis
7.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2020-2031)
7.3.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2020-2025)
7.3.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2026-2031)
7.4 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Country (2020-2031)
7.4.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Country (2020-2025)
7.4.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.5.2 USA Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.6.2 Canada Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.8.2 Germany Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.9.2 France Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.9.3 France Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.11.2 Italy Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.12.2 Spain Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.13.2 Russia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.16.2 China Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.16.3 China Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.17.2 Japan Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.19.2 India Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.19.3 India Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.20.2 Australia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.24.2 Chile Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.26.2 Peru Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.28.2 Israel Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.29.2 UAE Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.31.2 Iran Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Alkeus Pharmaceuticals
8.1.1 Alkeus Pharmaceuticals Comapny Information
8.1.2 Alkeus Pharmaceuticals Business Overview
8.1.3 Alkeus Pharmaceuticals Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2020-2025)
8.1.4 Alkeus Pharmaceuticals Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
8.1.5 Alkeus Pharmaceuticals Recent Developments
8.2 Biovista
8.2.1 Biovista Comapny Information
8.2.2 Biovista Business Overview
8.2.3 Biovista Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2020-2025)
8.2.4 Biovista Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
8.2.5 Biovista Recent Developments
8.3 Editas Medicine
8.3.1 Editas Medicine Comapny Information
8.3.2 Editas Medicine Business Overview
8.3.3 Editas Medicine Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2020-2025)
8.3.4 Editas Medicine Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
8.3.5 Editas Medicine Recent Developments
8.4 GenSight Biologics
8.4.1 GenSight Biologics Comapny Information
8.4.2 GenSight Biologics Business Overview
8.4.3 GenSight Biologics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2020-2025)
8.4.4 GenSight Biologics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
8.4.5 GenSight Biologics Recent Developments
8.5 Ixchel Pharma
8.5.1 Ixchel Pharma Comapny Information
8.5.2 Ixchel Pharma Business Overview
8.5.3 Ixchel Pharma Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2020-2025)
8.5.4 Ixchel Pharma Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
8.5.5 Ixchel Pharma Recent Developments
8.6 Khondrion
8.6.1 Khondrion Comapny Information
8.6.2 Khondrion Business Overview
8.6.3 Khondrion Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2020-2025)
8.6.4 Khondrion Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
8.6.5 Khondrion Recent Developments
8.7 Mitotech
8.7.1 Mitotech Comapny Information
8.7.2 Mitotech Business Overview
8.7.3 Mitotech Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2020-2025)
8.7.4 Mitotech Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
8.7.5 Mitotech Recent Developments
8.8 ProQR Therapeutics
8.8.1 ProQR Therapeutics Comapny Information
8.8.2 ProQR Therapeutics Business Overview
8.8.3 ProQR Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2020-2025)
8.8.4 ProQR Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
8.8.5 ProQR Therapeutics Recent Developments
8.9 Spark Therapeutics
8.9.1 Spark Therapeutics Comapny Information
8.9.2 Spark Therapeutics Business Overview
8.9.3 Spark Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2020-2025)
8.9.4 Spark Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
8.9.5 Spark Therapeutics Recent Developments
8.10 Stealth BioTherapeutics
8.10.1 Stealth BioTherapeutics Comapny Information
8.10.2 Stealth BioTherapeutics Business Overview
8.10.3 Stealth BioTherapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2020-2025)
8.10.4 Stealth BioTherapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
8.10.5 Stealth BioTherapeutics Recent Developments
8.11 Usher Syndrome
8.11.1 Usher Syndrome Comapny Information
8.11.2 Usher Syndrome Business Overview
8.11.3 Usher Syndrome Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2020-2025)
8.11.4 Usher Syndrome Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
8.11.5 Usher Syndrome Recent Developments
8.12 Amgen
8.12.1 Amgen Comapny Information
8.12.2 Amgen Business Overview
8.12.3 Amgen Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2020-2025)
8.12.4 Amgen Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
8.12.5 Amgen Recent Developments
8.13 Sanofi
8.13.1 Sanofi Comapny Information
8.13.2 Sanofi Business Overview
8.13.3 Sanofi Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2020-2025)
8.13.4 Sanofi Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
8.13.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Value Chain Analysis
9.1.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Mode & Process
9.2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Distributors
9.2.3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.